Promising Results With Epcoritamab Monotherapy in Relapsed/Refractory CLL

Published Date: 13 Dec 2024

Complete responses seen in 43% of patients in expansion cohort of EPCORE CLL-1 study

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

2.

Promising Results With Epcoritamab Monotherapy in Relapsed/Refractory CLL

3.

A Lot Can Be Said About You by Including Yourself in Photos.

4.

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot